After
Actelion was bought by
Johnson & Johnson in 2017, Idorsia was spun out into a new company and started operating on the same campus where Actelion was founded under the leadership of Actelion founders
Jean-Paul Clozel as CEO and
Martine Clozel as CSO. The company expects to be profitable in 2025. The main shareholder Jean-Paul Clozel provided Idorsia with a private loan of CHF 75 Mio. In the same month, Idorsia sold its operating businesses in
Japan and
South Korea to the Japanese firm Sosei Heptares for CHF 400 million. This includes the rights to market
clazosentan (Piviaz) and
daridorexant (Quviviq) in the
Asia Pacific region excluding
China, plus rights on two other treatments and up to five clinical-stage programs in Idorsia's pipeline. == Products ==